Spots Global Cancer Trial Database for relatlimab
Every month we try and update this database with for relatlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | NCT03623854 | Chordoma Locally Advance... Metastatic Chor... Unresectable Ch... | Nivolumab Relatlimab | 12 Years - | Jonsson Comprehensive Cancer Center | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | NCT03044613 | Gastric Cancer Esophageal Canc... GastroEsophagea... | Nivolumab Relatlimab Carboplatin Paclitaxel Radiation | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | NCT06325683 | Recurrent Gliob... | Biopsy Biospecimen Col... Lomustine Magnetic Resona... Nivolumab Relatlimab Surgical Proced... | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | NCT04204837 | Squamous Cell C... | Nivolumab Nivolumab plus ... | 18 Years - | Salzburger Landeskliniken | |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study | NCT05987241 | Muscle Invasive... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Biospecimen Col... cfDNA or ctDNA ... Computed Tomogr... Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | NCT04326257 | Squamous Cell C... | Nivolumab+Relat... Nivolumab+Ipili... | 18 Years - | University of Pittsburgh | |
| PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | NCT05034536 | Metastatic Mela... | Pembrolizumab Infliximab Placebo Relatlimab Nivolumab | 18 Years - | Massachusetts General Hospital | |
| Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | NCT04953104 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur... | Diagnostic Labo... Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | NCT03026140 | Colon Carcinoma | Nivolumab Ipilimumab Celecoxib 200mg BMS-986253 BMS-986016 | 18 Years - | The Netherlands Cancer Institute | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | NCT05337137 | Carcinoma, Hepa... | Relatlimab Nivolumab Bevacizumab Placebo | 18 Years - | Bristol-Myers Squibb | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | NCT04953104 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur... | Diagnostic Labo... Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | NCT03978611 | Melanoma | Relatlimab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | NCT06029270 | Metastatic Naso... Recurrent Nasop... Stage IV Nasoph... | Biospecimen Col... Bone Scan Carboplatin Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nivolumab Positron Emissi... Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | NCT06400264 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | NCT03310619 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | JCAR017 Durvalumab CC-122 Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | 18 Years - | Celgene | |
| Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | NCT05148546 | Renal Cell Carc... | Neoadjuvant niv... Neoadjuvant ipi... Neoadjuvant rel... | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | NCT03026140 | Colon Carcinoma | Nivolumab Ipilimumab Celecoxib 200mg BMS-986253 BMS-986016 | 18 Years - | The Netherlands Cancer Institute | |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | NCT04611126 | Metastatic Ovar... Metastatic Fall... Peritoneal Canc... | Ipilimumab Cyclophosphamid Fludarabine Pho... Tumor Infiltrat... Nivolumab Relatlimab | 18 Years - 75 Years | Herlev Hospital | |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | NCT04623775 | Non-small Cell ... Recurrent Non-s... Metastatic Non-... | Nivolumab Relatlimab Carboplatin Cisplatin Paclitaxel Nab-Paclitaxel Pemetrexed | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | NCT03724968 | Metastatic Mela... Advanced Melano... Metastatic Mela... | Nivolumab Relatlimab Ipilimumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | NCT03459222 | Advanced Cancer | Relatlimab Nivolumab BMS-986205 Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109 | Neoplasms by Si... | Relatlimab Nivolumab BMS-986213 | 12 Years - | Bristol-Myers Squibb | |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | NCT03459222 | Advanced Cancer | Relatlimab Nivolumab BMS-986205 Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | NCT03026140 | Colon Carcinoma | Nivolumab Ipilimumab Celecoxib 200mg BMS-986253 BMS-986016 | 18 Years - | The Netherlands Cancer Institute | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | NCT05034536 | Metastatic Mela... | Pembrolizumab Infliximab Placebo Relatlimab Nivolumab | 18 Years - | Massachusetts General Hospital | |
| Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | NCT04953104 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur... | Diagnostic Labo... Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Relatlimab in Combination With Nivolumab in Chinese Participants | NCT05498480 | Advanced Solid ... | Relatlimab Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | NCT05347212 | Carcinomas Renal Medullary... | Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG | NCT04062656 | Gastric Cancer Adenocarcinoma ... | Nivolumab relatlimab Oxaliplatin Docetaxel 5-Fluorouracil ... Folic acid (FA) | 18 Years - | University Hospital, Essen | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | NCT04112498 | Cancer | relatlimab nivolumab rHuPH20 | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | NCT03459222 | Advanced Cancer | Relatlimab Nivolumab BMS-986205 Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | NCT03743766 | Melanoma | Relatlimab Nivolumab Relatlimab + Ni... | 18 Years - | University of Pittsburgh | |
| Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | NCT04080804 | Head and Neck S... | Nivolumab Relatlimab Ipilimumab | 18 Years - | University of Pittsburgh | |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb | |
| Study of Relatlimab in Combination With Nivolumab in Chinese Participants | NCT05498480 | Advanced Solid ... | Relatlimab Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | NCT04658147 | Hepatocellular ... | Nivolumab Relatlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | NCT04567615 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... | Nivolumab Relatlimab | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | NCT04552223 | Metastatic Uvea... | Nivolumab Relatlimab | 18 Years - | University of Miami | |
| Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | NCT03642067 | Microsatellite ... Colorectal Aden... | Nivolumab Relatlimab Nivolumab Relatlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | NCT03521830 | Basal Cell Carc... | Nivolumab Ipilimumab Relatlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | NCT05148546 | Renal Cell Carc... | Neoadjuvant niv... Neoadjuvant ipi... Neoadjuvant rel... | 18 Years - | The Netherlands Cancer Institute | |
| Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | NCT04953104 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur... | Diagnostic Labo... Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | NCT05704647 | Melanoma (Skin) | BMS-986213 (Rel... Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | NCT02935634 | Advanced Gastri... | Nivolumab Ipilimumab Relatlimab BMS-986205 Rucaparib | 18 Years - | Bristol-Myers Squibb | |
| Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | NCT02966548 | Cancer | Relatlimab Nivolumab | 20 Years - | Bristol-Myers Squibb | |
| Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | NCT04080804 | Head and Neck S... | Nivolumab Relatlimab Ipilimumab | 18 Years - | University of Pittsburgh | |
| Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | NCT03623854 | Chordoma Locally Advance... Metastatic Chor... Unresectable Ch... | Nivolumab Relatlimab | 12 Years - | Jonsson Comprehensive Cancer Center | |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | NCT05328908 | Colorectal Neop... | Nivolumab-relat... Regorafenib TAS-102 | 18 Years - | Bristol-Myers Squibb | |
| Study of Relatlimab in Combination With Nivolumab in Chinese Participants | NCT05498480 | Advanced Solid ... | Relatlimab Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | NCT04326257 | Squamous Cell C... | Nivolumab+Relat... Nivolumab+Ipili... | 18 Years - | University of Pittsburgh | |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | NCT05625399 | Melanoma | Nivolumab + Rel... rHuPH20 | 12 Years - | Bristol-Myers Squibb | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | NCT06400264 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | NCT05002569 | Melanoma | Nivolumab Nivolumab + Rel... | 12 Years - | Bristol-Myers Squibb | |
| A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma | NCT05418972 | Stage II Melano... | Relatlimab and ... | 18 Years - | Melanoma Institute Australia | |
| An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | NCT02488759 | Various Advance... | Nivolumab Ipilimumab Relatlimab Daratumumab | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
